Ripretinib Dosage

Medically reviewed by Drugs.com. Last updated on Sep 13, 2024.

Usual Adult Dose for Gastrointestinal Stromal Tumor

Recommended dose: 150 mg orally once daily until disease progression or acceptable toxicity

Use: For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Recommended dose reduction for adverse reactions: 100 mg orally once daily.

• Permanently discontinue treatment in patients who are unable to tolerate this dose.

• Grade 2:
• Withhold treatment until Grade 1 or less or baseline. If recovered within 7 days, resume at same dose; otherwise resume at reduced dose.
• Consider re-escalating if maintained at Grade 1 or less or baseline for at least 28 days.
• If PPES recurs, withhold this drug until Grade 1 or less or baseline and then resume at a reduced dose regardless of time to improvement.

• Grade 3:
• Withhold treatment for at least 7 days or until Grade 1 or less or baseline (maximum 28 days). Resume at a reduced dose.
• Consider re-escalating if maintained at Grade 1 or less or baseline for at least 28 days.

• Grade 3:
• If symptomatic, withhold treatment until symptoms have resolved and blood pressure is controlled.
• If blood pressure is controlled to Grade 1 or less or baseline, resume at the same dose; otherwise, resume at a reduced dose.
• If Grade 3 hypertension recurs, withhold treatment until symptoms have resolved and blood pressure is controlled. Resume at a reduced dose.

• Grade 4:
• Permanently discontinue treatment.

• Grade 3 or 4:
• Permanently discontinue treatment.

• Grade 2:
• Withhold treatment until Grade 1 or less or baseline. If recovered within 7 days, resume at same dose; otherwise resume at reduced dose.
• Consider re-escalating treatment if maintained at Grade 1 or less or baseline for at least 28 days.
• If arthralgia or myalgia recurs, withhold treatment until Grade 1 or less or baseline and then resume at a reduced dose regardless of time to improvement.

• Grade 3:
• Withhold treatment for at least 7 days or until Grade 1 or less or baseline (maximum of 28 days). Resume at a reduced dose.
• Consider re-escalating this drug if maintained at Grade 1 or less or baseline for at least 28 days.

• Grade 3 or 4:
• Withhold treatment until Grade 1 or less or baseline (maximum 28 days), and then resume at a reduced dose; otherwise, permanently discontinue.
• Consider re-escalating treatment if no recurrence of the adverse reaction for at least 28 days.
• If Grade 3 or 4 recurs, permanently discontinue treatment.

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• This drug may be taken with or without food.
• Tablets should be swallowed whole; do not crush, chew, or dissolve.
• This drug should be taken at the same time each day.
• A missed dose should be taken if less than 8 hours have passed since the missed scheduled dose.
• An additional dose should not be taken if vomiting occurs after taking. The next scheduled dose should be taken.

• Store in the original container at room temperature between 20C to 25C (68F to 77F).

• Adverse reactions: See the warnings section for additional information.

• Read the Patient Information Leaflet.
• Consult your healthcare provider if you are pregnant or planning to become pregnant. There is a potential risk to a developing fetus.
• Females of reproductive potential should use effective contraception during treatment and for one week after the last dose.
• Males with females of reproductive potential should use effective contraception during treatment and for one week after the last dose as this medication may impair fertility.
• Breastfeeding is not recommended during treatment and for one week after the last dose.
• Inform your healthcare provider of all concomitant medications.
• This medication contains lactose.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer